340B Drug Pricing Program
To ensure good stewardship of the 340B program, hospitals participating in the program should structure hospital policies and practices to demonstrate their commitment. That demonstration of commitment includes sharing publicly how 340B savings are used to benefit the community, by, for example…
The AHA today expressed support for the Closing Loopholes for Orphan Drugs Act, H.R. 4538, bipartisan legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals.
The Centers for Medicare & Medicaid Services yesterday proposed surveying hospitals about their acquisition costs for specified covered outpatient drugs under the 340B drug savings program.
In a letter to Representatives Peter Welch and David B. McKinley:The AHA expresses support for H.R. 4538, the Closing Loopholes for Orphan Drugs Act.
The AHA appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ hospital outpatient prospective payment system and ambulatory surgical center payment system proposed rule for calendar year 2020.
The Centers for Medicare & Medicaid Services July 29 released the calendar year 2020 outpatient prospective payment system/ambulatory surgical center proposed rule.
Tax-exempt hospitals in the 340B drug savings program provided $56.1 billion in total benefits to their communities in 2016, the most recent year for which data is available, according to an analysis released today by the AHA.